Katja Tepeš, Jurij Hanžel, David Štubljar, Karin Strmšek, Luka Erjavec, Eva Supovec, Zala Jagodic, Mirjam Končan, Jan Grosek, Jurij Aleš Košir, Aleš Tomažič, Urška Kogovšek, Gregor Norčič, Renata Šibli, Marija Žnidaršič, Tadeja Pačnik Vižintin, Barbara Sodin, Janez Breznik, Vanesa Anderle Hribar, Andreja Ocepek, Cvetka Pernat Drobež, Nejc Bukovnik, Andrej Zafošnik, Tamara Marušič, Nataša Jurečič Brglez, Maja Denkovski, Nataša Smrekar, Gregor Novak, Matic Koželj, Tina Kurent, Jože Simonič, Špela Pintar, Borut Štabuc, David Drobne
BACKGROUND: With the increasing number of inflammatory bowel disease (IBD) patients, it is difficult to manage them within specialised IBD teams in academic medical centres: many are therefore treated in nonacademic IBD centres. It is unclear whether the time to introducing biologics is the same in both settings. AIM: We aimed to compare treatment approach with biologics in academic vs. nonacademic centres. METHODS: We analysed Slovenian national IBD registry data (UR-CARE Registry, supported by the European Crohn's and Colitis Organisation), which included 2 academic (2319 patients) and 4 nonacademic IBD (429 patients) centres...
April 2, 2024: European Journal of Gastroenterology & Hepatology